Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

ENSEM Raises $67 Million in A Round for Structure-Based Oncology Drugs

publication date: Apr 7, 2022

Boston’s ENSEM Therapeutics closed a Series A2 financing that brings its total Series A to $67 million. Incubated by CBC group since 2021, ENSEM is a biotech focused on difficult-to-drug oncology targets, using its Kinetic EnsembleTM platform to develop small molecule precision medicines for oncology. ENSEM integrates computational and AI deep learning technology with experimental validation to identify novel binding pockets and accelerate structure-based drug design. The A2 round was led by GGV Capital, with participation from Pavilion Capital, Cenova Capital, Mitsui and CBC Group. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital